The company processes and markets rice and edible oils, operating integrated milling and refining facilities to serve domestic retail markets in Eastern India and international export markets.
The company operates in a highly commoditized industry where margins are thin (1.8% net margin). While they are attempting to build brand equity through labels like Bhojmoti and Odaana, the low ROCE of 10% suggests they lack significant pricing power or cost advantages over competitors.
Management has focused on vertical integration and capacity expansion, notably the NCLT acquisition of the Haldia refinery and the merger of five subsidiaries to consolidate the balance sheet. However, the negative cash conversion and high debt-to-equity ratio indicate aggressive expansion that has yet to yield superior returns on capital.
The aggressive expansion strategy, fueled by high leverage and the NCLT acquisition, collapsed under the weight of a negative cash conversion cycle. As interest rates rose, the razor-thin 1.8% net margins were insufficient to service the debt, which had ballooned to over twice the equity. The company’s attempt to pivot from a commodity processor to a branded player failed as consumers remained price-sensitive, leaving the firm with idle capacity, massive capital advances locked in non-productive land, and a liquidity crunch that forced a fire sale of assets.
RichFakir rates Halder Venture Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Halder Venture Ltd is trading about 55% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Halder Venture Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Halder Venture Ltd's fair value is about ₹175 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →